Top Markets
Coin of the day
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Classement en actions #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Prix de l'action
$0.6379482
Dernière synchronisation: 2023-05-22
Capitalisation boursière
$5.98M
Changement (1 jour)
-0.44%
Changement (1 an)
0.00%
Pays
FR
Échange Nicox S.A. (COX)

Catégorie

EPS pour Nicox S.A. (COX)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Nicox S.A., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Nicox S.A. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE